Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Urinary Tract Infections Clinical Trial

Official title: Fractional CO2 Vaginal LASER Therapy for Recurrent Urinary Tract Infection

Status Completed

Clinical Trial Summary

Randomized controlled trial to determine clinical and microbiome difference between fractional CO2 Laser and vaginal estrogen in treating patients with recurrent urinary tract infection (UTI).

Clinical Trial Description

Recurrent urinary tract infection (rUTI) is common in postmenopausal women and can lead to significant bothersome symptoms. This clinical scenario is a difficult and common clinical problem seen by the urologist and urogynecologist with limited options for treatment. Overuse of antibiotics has led to significant resistant microorganisms and can have adverse side effects such as C. Dificile colitis. Current treatments include topical vaginal estrogen and prophylactic antibiotics. Other supplements such as cranberry pills, methenamine and D-mannose have varying levels of evidence and efficacy. Fractional CO2 LASER vaginal therapy has recently been studied for the treatment of GSM. LASER therapy is currently commercially available and has FDA clearance for use in gynecology. Current evidence shows that with treatment, histologic changes of the vaginal epithelium have shown regeneration to a premenopausal state, along with subjective improvement in GSM symptoms and sexual function. Recent literature has shown improvements in thickening of vaginal epithelium, decreased vaginal pH and improvement in the vaginal microbiome. Based on this, the investigators propose fractional CO2 laser may have a positive impact on women with rUTI. 1. The investigators therefore hypothesize that fractional CO2 LASER vaginal therapy is non-inferior to topical vaginal estrogen therapy for the treatment of rUTI. a. Primary Outcome: Improvement in recurrence of culture positive UTI 2. The investigators also hypothesize that LASER therapy will improve the urinary and vaginal microbiome, decreasing the uropathogenic presence and increasing Lactobacillus. 1. Measurement 1: The number of UTI with UPEC isolated from patients 2. Measurement 2: The pH of the vagina as a proxy for presence of Lactobacillus sp. 3. Measurement 3: Categorize vaginal and urinary microbial communities 3. The investigators hypothesize that LASER therapy will improve symptoms of GSM and be associated with regenerative change in vaginal histology. 1. Measurement 1: MESA and DIVA surveys of symptoms 2. Measurement 2: Observations of vaginal biopsy between. Menopausal women will be recruited if subjects have recurrent UTI defined as 3 culture positive UTIs in 1 year or 2 culture positive UTIs in 6 months. Subjects will be randomized to standard of care with topical vaginal estrogen or 3 treatments of fractional CO2 LASER of the vagina. Samples will be collected to show microbiome and histologic changes with treatment. Samples include: Vaginal culture Urine culture vaginal biopsy (optional). Validated questionnaires and clinical recurrence of UTI will also be gathered over 6 months. ;

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Urinary Tract Infections

• NCT number: NCT04301934
• Study type: Interventional
• Source: Mayo Clinic
• Status: Completed
• Phase: N/A
• Start date: June 1, 2020
• Completion date: April 30, 2023